Topical pilocarpine for xerostomia in patients with head and neck cancer treated with radiotherapy
| Autor: | R. M. S. Pereira, Vinícius Pedrazzi, Harley Francisco de Oliveira, Ana Carolina Fragoso Motta, Mônica Danielle Ribeiro Bastos, Ana Paula Macedo, Leandro Dorigan de Macedo, Osvaldo de Freitas, Hilton Marcos Alvez Ricz, Maíra P. Ferreira, Camila Tirapelli |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
business.industry
medicine.medical_treatment Head and neck cancer 030206 dentistry medicine.disease Dry mouth Placebo Clinical trial Radiation therapy 03 medical and health sciences 0302 clinical medicine Otorhinolaryngology Quality of life Pilocarpine 030220 oncology & carcinogenesis Anesthesia medicine In patient medicine.symptom business MEDICAMENTO TÓPICO General Dentistry medicine.drug |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP PEDRAZZI V |
| Popis: | Objective To evaluate a pilocarpine spray as a treatment for xerostomia in patients treated with radiotherapy (RT) for head and neck cancer (HNC). Methods This was a placebo-controlled, double-blind, crossover clinical trial of patients complaining of dry mouth after RT for HNC. Forty patients were randomly assigned to either placebo or pilocarpine (1.54%) spray and instructed to use three times a day for 3 months. After 1-month washout period, patients were crossed over to receive placebo or pilocarpine. The assessments were salivary flow (Stimulated Whole Saliva Flow - SWSF), xerostomia (Xerostomia Inventory - XI), and quality of life (QoL/Oral Health Impact Profile - OHIP-14), assessed at baseline, 1 hr (only SWSF), and at 1, 2, and 3 months of treatment. Results Posttreatment SWFS was not statistically different between pilocarpine and placebo regardless of the treatment sequence (paired T test; p > .05), except for the SWFS rates at 2 months after therapy. When comparing pilocarpine with placebo in the time points, there was no significant difference (p > .05) for QoL or XI. Significant differences in improvement in QoL and xerostomia experience appeared along time for pilocarpine group. Conclusion The topical application of pilocarpine spray tested was similar to placebo on SWSF assessments in patients treated with RT for HNC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|